The molecular classification of gliomas has revealed fundamental distinctions between IDH-mutant and IDH-wildtype tumors, with IDH-mutant lower-grade gliomas representing a distinct entity with unique therapeutic vulnerabilities and prognostic implications [4]. This evidence concerns the gene IDH1 and central nervous system cancer.